Hudson Biotech

Hudson Biotech is a clinical-stage biotechnology company based in Hawthorne, New York, focused on the development of novel peptide-based therapies for dermatology and musculoskeletal conditions. The company's lead programs include Melanotan II (MT-II), a synthetic melanocortin receptor agonist being evaluated in Phase 2 clinical trials for the repigmentation of stable nonsegmental vitiligo, and BPC 157, a pentadecapeptide being investigated for the repair of acute hamstring muscle strains. Hudson Biotech leverages its expertise in peptide synthesis and clinical development to address unmet needs in tissue repair and pigmentary disorders. The company maintains strategic ties to international research partners and is a participant in New York State's Excelsior Jobs Program.